Literature DB >> 24988576

New FDA breakthrough-drug category--implications for patients.

Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24988576     DOI： 10.1056/NEJMc1405337

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Accelerating innovation in rapid diagnostics and targeted antibacterials.

Authors:  Thomas J Hwang; John H Powers; Daniel Carpenter; Aaron S Kesselheim
Journal:  Nat Biotechnol       Date:  2015-06       Impact factor: 54.908

2.  A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.

Authors:  Minette-Joëlle Zeukeng; Enrique Seoane-Vazquez; Pascal Bonnabry
Journal:  Eur J Clin Pharmacol       Date:  2018-02-22       Impact factor: 2.953

Review 3.  Perspectives on research activity in the USA on Cancer Precision Medicine.

Authors:  Hideaki Bando; Naoko Takebe
Journal:  Jpn J Clin Oncol       Date:  2015-11-02       Impact factor: 3.019

4.  Pivotal clinical trials of novel ophthalmic drugs and medical devices: retrospective observational study, 2002-2012.

Authors:  Jenny Hwang; Thomas J Hwang; Joseph B Ciolino
Journal:  BMJ Open       Date:  2015-06-04       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.